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Abstract: Background: Several studies have indicated that chronic low-grade inflammation is
associated with the development of schizophrenia. Given the role of diet in modulating inflammatory
markers, excessive caloric intake and increased consumption of pro-inflammatory components
such as calorie-dense, nutrient-sparse foods may contribute toward increased rates of schizophrenia.
This study aimed to examine the association between dietary inflammation, as measured by the dietary
inflammatory index (DII®), and schizophrenia. Methods: A total of 120 cases attending the out-patient
department in the Psychiatric Hospital/Bahrain were recruited, along with 120 healthy controls
matched on age and sex. The energy-adjusted DII (E-DII) was computed based on dietary intake
assessed using a comprehensive food frequency questionnaire (FFQ). Logistic regression was used to
estimate odds ratios and 95% confidence intervals, adjusting for potential confounders including age,
sex, body mass index, education, employment, diabetes, hypertension, and cardiovascular disease
with E-DII expressed both as a continuous variable and categorized as quartiles. Results: The mean
E-DII score for the entire sample was 1.79 ± 1.52, indicating a generally pro-inflammatory diet.
The cases with schizophrenia appeared to have a higher E-DII score compared to controls: 1.99 ± 1.39
vs. 1.60± 1.38, respectively (p = 0.009). For every one unit increase in the E-DII score, the odds of having
schizophrenia increased by 62% (OR 1.62; 95% CI 1.17–2.26). Similarly, increased risk was observed
when the E-DII was used as quartiles, with participants in most pro-inflammatory quartile 4 being
nearly 6 times more likely to be schizophrenic than participants in the most anti-inflammatory group
quartile 1 (OR 5.96; 1.74–20.38; p-trend = 0.01). Conclusions: The data suggest that a pro-inflammatory
diet, as indicated by increasing E-DII score, is associated with schizophrenia. This is the first study to
examine the association between the DII and schizophrenia in a Middle Eastern population. Although
these results are consistent with findings from research conducted in depression, additional studies
are required before generalizing the findings to other populations.
Keywords: dietary inflammatory index (DII); schizophrenia; case–control study
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1. Introduction
Patients with schizophrenia die approximately 20 years earlier than individuals in the general
population, even after controlling for the risk of suicide and accidents [1]. The vast majority of early
deaths in patients with schizophrenia are attributable to preventable medical conditions, namely
cardiovascular disease (CVD) and chronic obstructive pulmonary disease (COPD), metabolic syndrome,
type 2 diabetes (T2DM), and some types of cancer [2–6]. Recent research shows that dietary components
are recognized to exert various effects on inflammation and their links with many diseases [7]. Therefore,
having a comprehensive understanding of modifiable risk factors and their link with inflammation is
essential to mitigate or prevent premature mortality.
Low-grade systemic inflammation is characterized by the continuous presence of pro-inflammatory
cytokines through increased blood flow during injury, which is known to play an essential role in
the development of illnesses and related mortality [8]. Several meta-analyses have shown that
increased risk of mortality (e.g., CVD, cancers, and COPD) is associated with higher intake of
pro-inflammatory processed food [5,8,9]. A large body of evidence supports the role of inflammation
in the pathophysiology of mental health disorders [10–12]. For example, the literature on the DII and
depression is sufficiently robust to have produced one meta-analyses, and many other studies have
been published recently on the topic [13–21]. Environmental factors have been found to substantially
impact the pathogenesis of psychiatric disorders including schizophrenia [22–25], with dietary patterns
having been shown to modulate the inflammatory state, thus, highlighting their potential role as
an etiologic factor or therapeutic tool in disorders with an inflammatory basis [9,17,26,27]. Indeed,
a recent review indicates that diet-associated inflammation may be associated with severe mental
illness, including schizophrenia [8].
For patients with schizophrenia, psychotropic medications are essential components of
management. Many of these medications are associated with significant weight gain, central obesity,
and development of metabolic disorders. A recent meta-analysis suggests that one of the key factors
underlying these cardiometabolic abnormalities are the effects of antipsychotic medications on excessive
energy intake and poor diet quality [28]. Patients on anti-psychotic medications report increased
appetite and increased cravings for sweet foods and beverages, and reduced intake of healthy foods
such as vegetables and fruits [29,30]. This craving makes them more susceptible to consuming a diet
with increased inflammatory potential that will worsen their condition.
The Dietary Inflammatory Index (DII®) is a novel literature-derived, population-based index
developed to assess the inflammatory potential of a person’s diet [31]. Its purpose is to evaluate the
quality of diet based on its inflammatory potential. The index places the individual on a continuum
from maximally anti-inflammatory diet to maximally pro-inflammatory diet. The DII was based on the
literature on six inflammatory markers C-reactive protein (CRP), interleukin (IL)-6, IL-1β, IL-10, IL-4,
and Tumor Necrosis Factor (TNF) α [31] related to any dietary factor. A high DII score represents a
more pro-inflammatory diet, whereas lower DII scores represent a more anti-inflammatory diet [31].
The DII has been shown to be validated with a variety of inflammatory markers including CRP, IL-6,
TNF, homocysteine and others in several studies [32–35]. With respect to mental health disorders,
the DII has been shown to be associated with depression [19,20], anxiety [27], cognitive decline [36,37],
and severe mental disorders, including schizophrenia [8,9].
This study is the first to assess the association between the inflammatory potential of foods
consumed by patients with schizophrenia (as measured through the DII) in comparison to age- and
sex-matched controls in a Middle Eastern population.
2. Materials and Methods
The guidelines of the Strengthening the Reporting of Observational Studies in Epidemiology
(STROBE) Statement) were adopted in planning, implementing, and reporting the study [38].
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2.1. Setting
Recruitment of cases with schizophrenia was carried in the Psychiatric Hospital, Ministry of
Health, Kingdom of Bahrain. The Psychiatric Hospital is the national center for diagnosis, treatment,
and rehabilitation of patients with severe mental illness in the nation of Bahrain. Data were collected
from patients between March and December 2016.
2.2. Sample Size and Sampling Procedure
The sample size was estimated for this study using a projected sample size for a matched
case–control study. This was based on an asymptotic z test, with a 1:1 ratio of matched design assuming
an OR = 2.0 of exposure in cases relative to controls. The sample size was estimated for the two-sided
test with error probabilities of α = 0.05 and 80% power (β = 0.20). Approximately 100 cases were
necessary for powered analysis; thus, we included 120 cases to further power our research. Sample size
calculation was performed using Stata 15.0 (StataCorp LLC., College Station, TX, USA). The sample of
schizophrenia cases was selected using simple random sampling technique from the case registry.
2.3. Participants
This study was performed using a case–control design. Cases with schizophrenia (N = 120) were
included based on these inclusion criteria: Either sex, aged between 20–60 years, diagnosed with
any schizophrenia of any type according to the International Statistical Classification of Diseases 10th
Revision, and were attending the out-patients department (OPD). Patients who were pregnant/lactating,
who were dieting, or were participating in lifestyles interventions or clinical trials were excluded
from the study. The control group was selected randomly from the primary health care centers and
based on matching the demographic characteristics, including age (by exact year of birth) and sex.
The exclusion criteria for the control group were the presence of a positive history of psychiatric
illness, a serious medical condition (e.g., cancer, SLE), being pregnant/lactating women, and those
who had been dieting during the past six months. The ratio of recruitment was 1:1; thus, for each
case, one control was enrolled. A simple randomization technique was used after matching to select
the right control. The majority of the population in the OPD are with three to eight years of history
with schizophrenia.
2.4. Ethical Consideration
Ethical approval for this study was obtained from the Research Ethics Committee, Ministry of
Health, Kingdom of Bahrain (according to the meeting number 02/2016). Written informed consent
was sought and obtained from the participants before collecting data. Participation in this study was
entirely voluntary, with no monetary or non-monetary incentives.
2.5. Assessments and Data Collection
All of the participants were interviewed in order to collect the required information for the study.
During the interview, anthropometric measurements (body weight and height) also were taken. Digital
scales were used to measure participant’s weight, with a height rod attachment that was kept on a
firm horizontal surface. Weight was recorded to the nearest 0.1 kg with the participants wearing light
clothes and not wearing shoes. The height was measured with the rod attached to the weighing scale
to the nearest 1.0 cm, and body mass index (BMI, kg/m2) was calculated from measured weight and
height. The BMI was then categorized as per the World Health Organization (WHO) categories of
underweight, normal, overweight, or obese.
The questionnaire comprised of demographics, medical history, psychiatric history for the cases,
and selected lifestyle factors including smoking status, physical activity level, and sleep. Dietary
intake was assessed using a semi-quantitative food frequency questionnaire (FFQ) [29]. The FFQ
was used to assess the frequency of food consumption in the study sample. Participants were asked
Nutrients 2019, 11, 1867 4 of 14
to report their usual frequency of consumption, on average, during the past month that they had
consumed a standard serving of a specific food item. The frequency response was categorized into
six categories (1 time/day, ≥2 times/day, 1–2 times/week, 3–6 times/week, 1–3 times/month, rarely
or never). Each food was specified in standardized serving size, and portion size photographs and
geometrical models were used to clarify the serving sizes for vegetables, meat, rice, milk, and other
food items. See Supplementary 1, the research questionnaire.
2.6. DII Score
Dietary intake assessed using the FFQ were analyzed using ESHA Nutrition and Fitness software
(ESHA Food Processor SQL, version 10.1.1, Salem, OR, USA). These nutrients were analyzed for each
subject recruited into the study. As ESHA software was developed for Western countries, Bahraini
traditional and conventional single and composite foods and dishes not included in ESHA database
were created and introduced into the database, either by formulating the recipe for composite dishes
using the available ingredients in the software, or inserting the nutritional value for that single food or
composite dish as obtained from local food composition tables, and then introducing it into the ESHA
database. The original DII consists of 45 nutrient and nutritional factors. However, most studies that
use an FFQ for dietary assessment cannot account for all of the components. A complete description
of the process of developing the DII has been published elsewhere [31,39]. Briefly, the dietary data
of the sample was first linked to the world database that provided a robust estimate of a mean and
SD for each parameter [31]. This was achieved by subtracting the “standard global mean” from the
intake reported via the FFQ and dividing this value by the standard deviation (SD) to obtain “z”
scores. To minimize the effect of “right skewing,” these “z” scores were then converted to a centered
proportion. The centered proportion for each food parameter for each individual was then multiplied
by the respective food parameter effect score (inflammatory potential for each food parameter), which
was derived from the literature review, to obtain a food parameter-specific DII score for an individual.
All of the food parameter–specific DII scores were then summed to create the overall DII score for each
participant in the study [31]. Finally, Energy-adjusted DII (E-DII) scores were calculated using the
density method wherein all food parameters were converted to per 1000kcal of nutrients and the same
procedure was used to relate individual exposure data to the global energy-adjusted database. In the
present study, the available components that were used for calculating E-DII included the following
nutrients: Energy, carbohydrates, fiber, protein, fat, saturated fatty acids (SFAs), polyunsaturated
fatty acids (PUFAs), monounsaturated fatty acids (MUFAs), omega-3 fats, omega-6 fats, saturated fat,
cholesterol, trans-fat, vitamins B12, B6, beta-carotene, folic acid, niacin, pyridoxine, riboflavin, thiamin,
vitamins A, C, D, and E; zinc, selenium, iron, magnesium; caffeine, and alcohol. Higher E-DII scores
indicate a more proinflammatory diet, whereas lower scores indicate a more anti-inflammatory diet.
2.7. Statistical Analyses
Descriptive statistics were used to summarize participants’ sociodemographic characteristics
across quartiles of the E-DII, as were the distribution of food group intakes across quartiles of E-DII.
The mean and standard deviation (SD) was reported for continuous variables, and count and percentage
were reported for categorical variables. To compare the two groups (cases and controls) an independent
sample t-test was used for continuous variables and Chi square was used for categorical variables.
This study consisted of cases and controls matched on sex and age. Therefore, appropriate
analytical statistics were used to examine the association between E-DII and schizophrenia status.
In addition to matching for age and sex during the design phase, we further controlled in the analyses
for body mass index, education, employment, diabetes, hypertension, and cardiovascular disease.
The E-DII was analyzed both as a continuous variable and categorized by quartiles of exposure.
Logistic regression was performed, and odds ratio (OR) and 95% confidence intervals (95%CI) were
calculated, and significance was considered at p-value < 0.05. All analyses were performed using Stata
15.0 software. Quartiles of E-DII scores were calculated based on the distribution of E-DII among
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controls according to the following ranges: Quartile 1 ≤0.71, Quartile 2 0.71–1.78, Quartile 3 1.79–2.45
and Quartile 4 ≥2.46.
3. Results
The mean E-DII score for the entire Bahraini sample (cases and controls) was 1.79 ± 1.52, which
indicates a pro-inflammatory diet. The cases with schizophrenia appeared to have a statistically
higher E-DII score compared to their corresponding age- and sex-matched controls (1.99 ± 1.39 and
1.60 ± 1.38, respectively, p = 0.009). Table 1 describes the distribution of several sociodemographic
and health indicators according to schizophrenia status. Cases with schizophrenia were more likely
to be obese (46.7%), physically inactive (76.7%), currently smokers (61.7%), short-duration sleepers
(43.3%), and have higher risks to type 2 diabetes mellitus (30.8%), hypertension (31.7%), CVD (8.3%),
and muscular and joints disease (36.7%). Furthermore, cases with schizophrenia appeared to have
lower socioeconomic indicators, including lower education level, and to be unemployed and single.
Table 1. Socio-demographic characteristics of schizophrenia cases and healthy controls.
Characteristic Variable Cases Controls p-Value
Continuous variables (mean ± SD)
Age (years) 41.69 ± 13.00 41.63 ± 13.24 0.96
Weight (Kg) 83.58 ± 23.05 77.43 ± 17.02 0.02 *
Height (cm) 165.39 ± 9.01 166.98 ± 9.61 0.19
Body mass index (BMI) (Kg/m2) 30.65 ± 9.24 27.58 ± 6.25 0.003 *
Categorical variables:
Male (%) 55 55 -
Overweight (%) 23.33 37.27 0.40
Obese (%) 46.67 27.73 0.002 *
Education level (%)
• Primary or less 36.7 10.8
0.001 *• Secondary 43.3 30.0
• Tertiary 20.0 59.2
Job (%)
• Un-employed 43.3 0.8
0.001 *• Employed/Student 39.2 85.0
• Retired 17.5 14.2
Marital status (%)
• Married/Engaged 30.00 79.17
0.001*
• Single 55.00 14.17
• Divorced 14.17 3.33
• Widow/er 0.83 3.33
Physical activity level (%)
• Inactive 76.67 40.00
0.001 *
• Active 23.33 60.00
Current smoking status (%)
• Nonsmoker 61.67 85.83
*
• Smoker 38.33 14.17
Smoking type (%)
• Cigarettes 58.70 64.71
0.001 *
• Water Pipe 4.35 11.76
• Mixed 36.95 17.65
• Electronic Cigarette 0.0 5.88
Medical comorbidity (%)
• Type 2 Diabetes mellitus 30.83 10.00 0.001 *
• Hypertension 31.67 14.17 0.001 *
• Cardio vascular disease 8.33 5.83 0.45
• Muscular & joints disease 36.67 23.33 0.02 *
Adequate Sleep (%) 56.67 92.44 0.001 *
* Cases were significantly different from controls at p < 0.05.
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Supplementary Table S1 describes the distribution of the health and socio-demographic
characteristics across quartiles of E-DII for the controls, while Table 2 describes the distribution
of health and sociodemographic characteristics across quartiles of E-DII scores for cases with
schizophrenia. According to Supplementary Table S1, Bahraini controls in the most pro-inflammatory
group (i.e., quartile 4) were more likely to have higher BMIs, be physically inactive, be current smokers,
and had inadequate sleep. For the patients with schizophrenia (Table 2), quartile 1 included more
patients who were obese and overweight; patients in quartile 2 were mostly single, unemployed and
have a higher prevalence of T2DM or hypertension; patients in quartile 3 were physically inactive and
current smokers.
Table 2. Characteristics of schizophrenia case participants across the quartiles of energy-adjusted
Dietary Inflammatory Index (E-DII).
Characteristic Quartile 1 Quartile 2 Quartile 3 Quartile 4
Age (years): Mean ± SD 46.44 ± 15.00 41.25 ± 14.16 43.66 ± 12.51 37.56 ± 10.00
Body mass index (BMI) (Kg/m2): Mean ± SD 30.69 ± 6.64 30.64 ± 9.47 31.10 ± 11.90 30.28 ± 8.12
Overweight (%) 31.81 19.36 23.33 21.62
Obese (%) 54.55 45.16 46.67 43.24
Education (%)
• Primary 26.7 40 41.9 37.9
• Secondary 56.7 20 41.9 34.5
• Tertiary 16.7 20 16.1 27.6
Job (%)
• Unemployed 40 50 38.7 44.8
• Employed/Student 43.3 40 32.3 41.4
• Retired 16.7 10 29 13.8
Social Status (%)
• Married/Engaged 30 26.7 45.2 17.2
• Single 50 63.3 38.7 69
• Divorced 20 6.7 16.1 13.8
• Widow/er 0 3.3 0 0
Physical activity (%):
• Inactive 73.3 76.7 83.9 72.4
• Active 26.7 23.3 16.1 27.6
Smoking (%)
• Nonsmoker 36.3 66.7 58.1 58.6
• Smoker 36.7 33.3 41.9 41.4
Smoking Type (%)
• Cigarette 54.5 60 76.9 41.7
• Water Pipe 9.1 10 0 0
• Mixed 36.4 30 23.1 58.3
Medical Comorbidity (%)
• Type 2 Diabetes mellitus 36.7 36.7 32.3 17.2
• Hypertension 33.3 36.7 32.3 24.1
• Cardiovascular disease 6.7 13.3 6.5 6.9
• Muscular & joints disease 36.7 43.3 22.6 44.8
Adequate Sleep (%) 50 66.7 45.2 65.5
Supplementary Table S2 and Table 3 shows the distribution of food groups’ intake across quartiles
of E-DII scores for controls and cases, respectively. Most pro-inflammatory nutrients or foods
components such as energy, protein, carbohydrates, fat, saturated fats, and cholesterol, all increased
linearly across the quartiles of E-DII. Likewise, anti-inflammatory dietary components such as fiber,
folic acid, β-carotene, Mg, Zn, vitamins C, and A decreased across quartiles. Pro-inflammatory
components that were consumed in higher quantities among subjects in the fourth quartile were
protein, carbohydrates, fat, saturated fat, MUFA, PUFA, trans- fat, cholesterol, omega-6 FAs, niacin,
and energy.
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Table 3. Distribution of nutrients and dietary factors across quartiles of energy adjusted Dietary
Inflammatory Index (E-DII) for schizophrenia cases.
Nutrient or Dietary
Factor/Day (Mean ± SD) Quartile 1 Quartile 2 Quartile 3 Quartile 4
Energy (Kcal) 2113.72 ± 512.3 2715.78 ± 832.29 2469.4 ± 814.44 2856.51 ± 810.95
Protein (g) 86.64 ± 20.72 115.87 ± 38.62 105.37 ± 30.31 116.29 ± 29.86
Carbohydrates (g) 310.06 ± 71.52 372.53 ± 117.92 322.52 ± 104.97 364.62 ± 109.32
Fibers (g) 26.53 ± 10.86 29.01 ± 13 20.55 ± 8.05 22.9 ± 9.75
Fat (g) 63.01 ± 21.31 90.49 ± 33.22 88.79 ± 35.98 108.11 ± 37.02
SFA (g) 22.94 ± 7.09 33.54 ± 10.94 31.39 ± 10.45 40.13 ± 13.02
MUFA (g) 8.18 ± 3.49 11.58 ± 6.12 12.96 ± 11 12.29 ± 6.1
PUFA (g) 9.06 ± 4.56 11.43 ± 5.7 13.25 ± 9.7 12.84 ± 5.4
Trans fats (g) 0.37 ± 0.24 0.43 ± 0.25 0.29 ± 0.16 0.37 ± 0.21
Cholesterol (mg) 372.7 ± 217.79 579.4 ± 300 501.72 ± 200.86 607.58 ± 248.07
Omega-3 (g) 0.59 ± 0.2 0.81 ± 0.34 0.93 ± 0.72 0.75 ± 0.38
Omega-6 (g) 7.55 ± 4.03 9.41 ± 4.81 11.29 ± 8.92 10.71 ± 4.63
Thiamin (mg) 1.29 ± 0.32 1.55 ± 0.49 1.45 ± 0.74 1.34 ± 0.4
Riboflavin (mg) 1.12 ± 0.35 1.54 ± 0.69 1.37 ± 0.8 1.27 ± 0.62
Niacin (mg) 16.02 ± 6.97 19.39 ± 9.59 17.32 ± 9.64 18.42 ± 7.43
Vitamin B6 (mg) 0.96 ± 0.29 1.09 ± 0.39 0.97 ± 0.65 0.87 ± 0.36
Vitamin B12 (µg) 1.88 ± 0.82 2.97 ± 1.8 3.41 ± 2.73 2.8 ± 2.31
Vitamin C (mg) 125.03 ± 44.08 105.75 ± 38.17 90.56 ± 37.39 88.09 ± 43.76
Vitamin D (IU) 64.86 ± 52.43 94.22 ± 72.07 76.7 ± 60.99 58.63 ± 59.94
Vitamin E (mg) 2.63 ± 1.1 3.13 ± 1.64 2.86 ± 1.85 3.11 ± 1.69
Folic Acid (µg) 458.82 ± 225.73 534.7 ± 212.28 373.91 ± 165.98 350.11 ± 129.41
Vitamin A (IU) 6472.23 ± 1953.38 6412.42 ± 2022.39 5066.16 ± 1980.85 4543.75 ± 1968.46
β-carotene (µg) 2737.61 ± 931.49 2455.61 ± 900.81 1966.68 ± 926.29 1527.49 ± 871.88
Iron (mg) 14.67 ± 4.73 17.76 ± 6.27 15.58 ± 7.91 14.94 ± 4.84
Magnesium (mg) 225.4 ± 98.21 249.91 ± 128.36 179.48 ± 77.05 199 ± 76.42
Selenium (µg) 55.73 ± 16.38 69.45 ± 25.69 63.76 ± 31.95 60.93 ± 17.07
Zinc (mg) 4.96 ± 1.57 6.4 ± 2.86 5.3 ± 2.58 5.07 ± 2.52
Alcohol (g) 0.05 ± 0.23 0 ± 0 0.26 ± 1.26 0.97 ± 2.82
Caffeine (mg) 179.51 ± 260.16 190.2 ± 208.82 95.38 ± 121.05 168.7 ± 171.97
ORs and 95% CIs for schizophrenia status according to quartiles of the E-DII are shown in Table 4.
Results obtained from modeling E-DII as a continuous variable in relation to schizophrenia suggested
a positive association after adjusting for age, sex, body mass index, education, employment, diabetes,
hypertension, and CVD in the analysis (OR 1.62; 95% CI 1.17–2.26). A similar association was observed
when E-DII was expressed as quartiles, with participants in most pro-inflammatory group (Quartile 4)
being almost six times more likely to be schizophrenic than participants in the most anti-inflammatory
group (Quartile 1) (OR 5.96; 1.74–20.38; p-trend = 0.01).
Table 4. Odds ratios (OR) and confidence intervals for quartiles of energy adjusted Dietary Inflammatory
Index (E-DII) associated with the diet of patients with Schizophrenia.
Quartiles of the Energy-Adjusted Dietary
Inflammatory Index *
Quartile 1 Quartile 2 Quartile 3 Quartile 4 E-DII(Continuous)
E-DII Range ≤0.07 0.71–1.78 1.79–2.45 ≥2.46
Cases/Controls 11/30 38/30 28/30 43/30 120/120
Multivariate-adjusted a 1 (Ref) 4.27(1.27–14.35)
2.78
(0.77–10.0)
5.96
(1.74–20.38)
1.62
(1.17–2.26)
* p trend = 0.01. a Adjusted for age, sex, body mass index, education, employment, diabetes, hypertension, and
cardiovascular disease.
4. Discussion
Underlying the relevance of this study are two related and profoundly important questions:
Does inflammation precede or follow neuropsychiatric disorders (such as schizophrenia) and (2) are
they causally related [40,41]. In an attempt to help answer these questions, the current study tried
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to examine the inflammatory potential of food intake of individuals with schizophrenia compared
with their corresponding controls in the Bahraini population. The positive association observed in this
study supports an association, thought the case–control design cannot comment on temporality and
therefore cannot provide strong causal inference.
The presence of a significant association between schizophrenic patients and the E-DII in the
current study mirrors a previous, larger-scale survey in the UK, where 254 schizophrenia patients
were found to have highly elevated DII scores in comparison with disease-free controls, after adjusting
for age, gender, and total energy intake [9]. Other studies have reported that higher levels of
dietary inflammation were observed in schizophrenic patients: The same group that also experiences
significantly worse physical health outcomes than other classes of severe mental illness [42,43].
According to the available literature and to best of our knowledge, this is the first case–control
study in the Middle East and Gulf Cooperation Council (GCC) region and second in the world tackling
the association between schizophrenia and dietary inflammation using the DII as a surrogate indicator
for the inflammatory potential of food consumed. Relevant case–control studies on schizophrenia
investigated different aspects of the inflammation–schizophrenia relationship. One study on Polish
schizophrenia patients detected a functional polymorphism in the proinflammatory cytokine IL-6
and the anti-inflammatory cytokine IL-10 genes in patients with paranoid schizophrenia [44]. Such a
polymorphism leads to a state of imbalance which, in turn, leads to increased levels of inflammation
that predisposes to the development and progression of schizophrenia. Findings from that study
were later confirmed by another case–control study, which showed that schizophrenic patients had
significant increases in intracellular components of a main proinflammatory pathway, along with a
substantial decrease in the anti-inflammatory ones [45].
Schizophrenia is an inflammation-related mental disorder [6,40,41,46–52], with variable
backgrounds including biological (hormonal and genetic), lifestyle behavioral and dietary habits that
predispose or accompany the development of that mental disorder [53,54].
There is mounting evidence indicating that the relationship between inflammation and mental
disorders, such as schizophrenia, is a two-way relationship. While neuropsychiatric disorders
(i.e., schizophrenia and mood disorders) facilitate inflammatory reactions; inflammation promotes
schizophrenia and other neuropsychiatric disorders [40]. It has been shown in repeated reports
that patients with neuropsychiatric disorders exhibit all classical features of inflammation, including
increased activated sensors, inflammatory mediators, and circulating levels of inflammatory inducers
targeting all tissues. Proinflammatory cytokines modulate cognition and mood behavior by inhibiting
neuroendocrine responses, lowering brain monoamine levels, impairing brain plasticity, and promoting
excitotoxicity (increased glutamate levels) [40]. The important triggering factors of inflammation
that predispose to developing schizophrenia include changes in neuroendocrine regulation [55,56],
metabolism [6,57–59], diet/microbiota [60–64], and adverse health behaviors such as smoking [65–68].
Finally, recent reports indicate that early-life stress is associated with inflammation before the
progression of neuropsychiatric disorders such as schizophrenia [69,70].
Considering that the DII is as a sensitive index for six inflammatory markers: CRP, IL-1β, IL-4, IL-6,
IL-10, and TNF-α [31]; it can be inferred that lowering the intake of pro-inflammatory, high-DII foods
and increasing the consumption of anti-inflammatory, low-DII foods would act as powerful adjuvant
therapy for schizophrenia patients [71]. This conclusion is reinforced by the fact that the aforementioned
pro-inflammatory cytokines are those mediators that are directly involved in the pathogenesis of
schizophrenia and its predisposed and associated elevated inflammatory state [47,49,65,67,72–74].
Further, other macro- and micro-nutrients involved in the calculation of DII are also involved in
maintaining healthy brain function and improving neuroplasticity, and thus nullify the progression
of schizophrenia or hinder its severity in diagnosed patients [51]. These nutrients include omega-3
polyunsaturated fatty acids, vitamin D, B vitamins (B6, folate, B12), vitamin E, and carotenoids [51].
Findings of the current study are consistent and in line with the general context regarding the
relationship between schizophrenia and inflammation. Our results are supported by cross-sectional
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studies showing that individuals with severe mental illnesses, particularly schizophrenia, consume
more pro-inflammatory foods and fewer anti-inflammatory nutrients than the general population [8,9].
This study has several strengths. It is the first study in Bahrain and Middle East to explore the
association between the inflammatory properties of the diet in relation to schizophrenia. Second,
the matched case–control design that allows for a relatively large sample resulting in relatively high
statistical power and the ability to control for several covariates. Third, the use of the DII as a research
tool allowed us to examine the overall diet rather than focusing on individual nutrients or foods.
Fourth, E-DII scores were computed using an FFQ that was specifically designed to capture the broad
range of diet in Bahrain. Despite its strengths, the study also has limitations, including the possibility
of both selection and information biases. Another limitation is that DII/ E-DII was not validated
with inflammatory markers in this study. Though it would have been ideal if we had information on
inflammatory markers, the study had already been conducted and the current analyses were dependent
on existing data. Thus, it was not be possible to perform validation analyses. To countervailed this
concern, however, it is important to note that the DII or E-DII have been validated in over 20 studies
with various inflammatory markers across the world, including Middle Eastern countries [33,34,75].
On balance, the current study adds to the existing evidence that schizophrenia is associated with
increased exposure to pro-inflammatory foods, as expressed by the DII/ E-DII. Future longitudinal
studies are recommended to assess how dietary inflammation is related to the onset of schizophrenia,
as no reliable evidence linking dietary inflammation with the risk of schizophrenia currently exists.
Future studies are encouraged to account for the duration and severity of mental illness using
well-known tools such as the Positive and Negative Syndrome Scale (PANSS) as a measure for
illness severity.
From the mental health practice perspectives, the patients’ assessment of quality of diet and
specifically the inflammatory properties of food appear to be an important practice in the care
of individuals with schizophrenia. This research raises the recommendation that patients with
schizophrenia should be regularly evaluated for dietary and lifestyle factors in order to improve the
outcomes of the illness.
From research perspectives, follow-up studies that would measure both DII and concentrations of
inflammatory cytokines in plasma, serum, and other body fluids are encouraged to better understand the
relationship between diet and schizophrenia. Furthermore, the effectiveness of anti-inflammatory diet
in the management of schizophrenia needs to be examined using randomized controlled clinical trials.
5. Conclusions
The current study shows that individuals with schizophrenia consume a more pro-inflammatory
diet, with fewer anti-inflammatory nutrients, than the general population. This, in turn, would imply
that instead of only changing the caloric intake of patients or the quality of the diet, researchers and
clinicians need to take into consideration the inflammatory role of the diet of patients with schizophrenia.
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